Clin Transl Gastroenterol. 2021;12(3):e00321.
Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study.
제1저자 Feng Gao · 교신저자 김원, Ming-Hua Zheng
소속 (8)
- Department of Gastroenterology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Department of Pathology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea.
- Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
- Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton, Southampton General Hospital, Southampton, UK.
- Institute of Hepatology, Wenzhou Medical University, Wenzhou, China.
- Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China.
Abstract
INTRODUCTION Strong evidence indicates that multiple genetic and environmental risk factors play a role in the pathogenesis of nonalcoholic steatohepatitis (NASH). We aimed to develop and validate a novel nomogram, incorporating both genetic and clinical factors, for predicting NASH.
METHODS A total of 1,070 Asian individuals with biopsy-confirmed nonalcoholic fatty liver disease (NAFLD) from 2 countries (China and South Korea) were recruited. The histological spectrum of NAFLD was classified according to the NASH clinical research network scoring system. The nomogram was developed in the Chinese training set (n = 402), and then, it was validated in both the Chinese internal validation set (n = 136) and the external Korean validation cohort (n = 532), respectively.
RESULTS Sex, metabolic syndrome, insulin resistance, serum aspartate aminotransferase levels, and PNPLA3 (rs738409) and HSD17B13 (rs72613567) genetic variants were strongly associated with NASH. Based on their regression coefficients, we developed a nomogram with good discriminatory ability (area under the receiver operating characteristic curve: 0.81, 95% confidence interval [CI] 0.77-0.85) and good calibration (Hosmer-Lemeshow test, P = 0.794) for identifying NASH. In the 2 validation cohorts, the nomogram showed high area under the receiver operating characteristic curves (internal validation set: 0.80, 95% CI 0.72-0.88; external validation cohort: 0.76, 95% CI 0.72-0.80) and good calibration.
DISCUSSION Our newly developed and externally validated nomogram, incorporating both genetic and clinical risk factors, may be conveniently used to predict NASH. Further validation studies in other ethnic groups are warranted to confirm its diagnostic utility to identify NASH, among patients with biopsy-proven NAFLD.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Figures
그림 출처: PubMed Central 공개 논문 (PMC7954375)
Conflict of interest statement
Guarantor of the article: Ming-Hua Zheng, MD, PhD. Specific author contributions: F.G. and M.-H.Z.: study concept and design. S.-D.C., X.-X.W., X.-D.W., D.H.L., and Y.-P.C.: acquisition of data. F.G. and K.I.Z.: drafting of the manuscript. W.K., G.T., and C.D.B.: critical revision. F.G. and S.-D.C.: statistical analysis. M.-H.Z. and W.K.: study supervision. All authors contributed to the manuscript for important intellectual content and approved the submission. Financial support: This work was supported by grants from the National Natural Science Foundation of China (82070588), Research Grant of Tianqing for Liver Disease (TQGB20200097), High Level Creative Talents from Department of Public Health in Zhejiang Province (S2032102600032), and Project of New Century 551 Talent Nurturing in Wenzhou. G.T. is supported in part by grants from the School of Medicine, University of Verona, Verona, Italy. C.D.B. is supported in part by the Southampton NIHR Biomedical Research Centre (IS-BRC-20004), UK. W.K. was supported by a National Research Foundation of Korea grant funded by the Korea government (2016R1D1A1B04934590), and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute funded by the Ministry of Health & Welfare, Republic of Korea (HI17C0912). Potential competing interests: None to report.
그 밖의 정보
- 출판 형태
- Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't, Validation Study
- 저널
- Clinical and translational gastroenterology · eISSN 2155-384X
- 전자 출판
- 2021-03-10
- MeSH
- 17-Hydroxysteroid Dehydrogenases / genetics · Adult · Biopsy · China / epidemiology · Cross-Sectional Studies · Female · Genetic Predisposition to Disease* · Humans · Insulin Resistance / genetics · Lipase / genetics · Liver / pathology · Male · Membrane Proteins / genetics · Metabolic Syndrome / epidemiology / genetics · Middle Aged · Nomograms* · Non-alcoholic Fatty Liver Disease / diagnosis / epidemiology / genetics / pathology · Polymorphism, Single Nucleotide · ROC Curve · Republic of Korea / epidemiology · Risk Assessment / methods · Risk Factors · Acyltransferases · Phospholipases A2, Calcium-Independent
- Substances
- 17-Hydroxysteroid Dehydrogenases · Lipase · Membrane Proteins · HSD17B13 protein, human · PNPLA3 protein, human · Acyltransferases · Phospholipases A2, Calcium-Independent
- 참고문헌
- 50편